NCT01670279View on ClinicalTrials.gov

Phase 1 Study to Assess the Safety/Tolerability of Brexpiprazole as Adjunctive Therapy in Elderly Subjects With Major Depressive Disorder

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

May 31, 2013

Study Completion Date

May 31, 2013

Conditions

Major Depressive Disorder

Interventions

DRUG

Brexpiprazole

up to 3mg oral dose once daily

DRUG

Placebo

Trial Locations (4)

Unknown

Accurate Clinical Trials, Kissimmee

Miami Jewish Health System, Miami

St. Louis Clinical Trials, St Louis

CRI Lifetree- Philadelphia Research Center, Philadelphia

All Listed Sponsors

collaborator

H. Lundbeck A/S

INDUSTRY

lead

Otsuka Pharmaceutical Development & Commercialization, Inc.

INDUSTRY

NCT01670279 - Phase 1 Study to Assess the Safety/Tolerability of Brexpiprazole as Adjunctive Therapy in Elderly Subjects With Major Depressive Disorder | Biotech Hunter | Biotech Hunter